https://www.selleckchem.com/pr....oducts/Cytarabine(Cy
To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus. In this 12-week study, patients receiving twice-daily premixed insulin therapy in group 1 ( = 55) were switched to twice-daily IDegAsp. In group 2 ( = 6, patients on intensive insulin therapy were switched to IDegAsp injected twice a day. Inter- and intragroup comparisons were made. A total of 115 patients were included in the stud
Like
Comment
Share
